Artiva Biotherapeutics, Inc. revenue

Revenue history

AnnualQuarterly

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Artiva Biotherapeutics, Inc.: revenue history, annual

Fiscal year	2023Dec 2023	2024Dec 2024	2025Dec 2025
Revenue	33	0	0
Growth on the year before	—	−99.3%	−100.0%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

Company	Revenue	Growth	3-year growth a year
Artiva Biotherapeutics, Inc.	$251,000	—	—
Clene Inc.	$197,000	-31.1%	-36.9%
Cervomed Inc.	$331,295	-95.7%	-52.7%
Celldex Therapeutics, Inc.	$158,000	-97.3%	-63.5%
Cardiff Oncology, Inc.	$508,000	-7.0%	7.2%
Ibio, Inc.	$100,000	-75.0%	-62.4%

Compare with peers

• Clene Inc. revenue
• Cervomed Inc. revenue
• Celldex Therapeutics, Inc. revenue
• Cardiff Oncology, Inc. revenue
• Ibio, Inc. revenue

Head to head: ARTV vs CLNNARTV vs CRVOARTV vs CLDX

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Artiva Biotherapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Artiva Biotherapeutics, Inc.